Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

AIDS (London, England) - 22 Nov 2002

Clevenbergh Philippe, Garraffo Rodolphe, Durant Jacques, Dellamonica Pierre

Abstract excerpt

OBJECTIVE: A randomized study to evaluate the usefulness of protease inhibitor (PI) therapeutic drug monitoring (TDM) in antiretroviral-experienced HIV-infected patients. METHODS: In the control arm, treatment was modified according to genotypic resistance testing. In the TDM arm, therapy was modified on the basis of genotypic resistance testing and at week 8 according to PI plasma trough levels measured at week...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to RNA, Viral

Share to Single-Blind Method

Source

Identifiers

PMID: 12441803
DOI: 10.1097/00002030-200211220-00011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.PMID 12441803Read ↗

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.Semantic proximity Read ↗

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.Semantic proximity Read ↗

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.Semantic proximity Read ↗

Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Semantic proximity Read ↗

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.Semantic proximity Read ↗

Tipranavir: a ritonavir-boosted protease inhibitor.Semantic proximity Read ↗

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.Semantic proximity Read ↗

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

[Boosted protease inhibitor monotherapy in HIV-infected patients: results of a study in a real life setting].Semantic proximity Read ↗

Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trial.Semantic proximity Read ↗

Principles and practice of HIV-protease inhibitor pharmacoenhancement.Semantic proximity Read ↗

A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.